Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
12/2002
12/05/2002WO2002096458A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002WO2002096435A2 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002WO2002096423A2 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002WO2002096422A2 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
12/05/2002WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002WO2002096406A1 Medicinal compositions
12/05/2002WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002WO2002096367A2 Targeted multivalent macromolecules
12/05/2002WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
12/05/2002WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002WO2002009637A3 Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
12/05/2002WO2001093840A2 Ligands of integrin receptors
12/05/2002WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002US20020183399 Method and compositions for treating rosacea
12/05/2002US20020183391 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
12/05/2002US20020183389 Preferably at least 95%, is in the form of eicosapentaenoic acid (EPA), and less than 5%, and preferably less than 3% is in the form of docosahexaenoic acid (DHA); useful for treating psychological and nervous system disorders
12/05/2002US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002US20020183362 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
12/05/2002US20020183360 Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels
12/05/2002US20020183326 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them
12/05/2002US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002US20020183316 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
12/05/2002US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient
12/05/2002US20020183269 Novel compounds
12/05/2002US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002US20020183255 Use of KPV tripeptide for dermatological disorders
12/05/2002US20020182703 Human defensin polypeptide Def-X, genomic DNA and cDNA, composition containing them and applications to diagnosis and to therapeutic treatment
12/05/2002US20020182683 Vascular endothelial growth factor 2
12/05/2002US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders
12/05/2002US20020182650 Inhibitors of binding between proteins and macromolecular ligands
12/05/2002US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect
12/05/2002US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
12/05/2002US20020182265 Lubricious coatings for substrates
12/05/2002US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini.
12/05/2002US20020182213 Method for the treatment of fibrosis
12/05/2002US20020182208 Glycosylated antibody
12/05/2002US20020182147 Vitronectin receptor antagonist pharmaceuticals
12/05/2002DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases
12/05/2002DE10125179A1 Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse Use of LPS to treat intestinal inflammation
12/05/2002DE10118282A1 Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and tackifier resins, for medical uses
12/05/2002CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002CA2448956A1 Anti-ngf antibodies for the treatment of various disorders
12/05/2002CA2448639A1 Novel heterocyclic derivatives and medicinal use thereof
12/05/2002CA2448627A1 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002CA2448562A1 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002CA2448509A1 4-hydroxypiperidine derivatives having analgesic activity
12/05/2002CA2448363A1 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002CA2448305A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002CA2448294A1 Method for treating fibrotic diseases or other indications vi
12/05/2002CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002CA2448192A1 Pyrimidine derivatives useful as selective cox-2 inhibitors
12/05/2002CA2448148A1 Carbohydrate-associated proteins
12/05/2002CA2448146A1 Secreted proteins
12/05/2002CA2448116A1 Molecules for disease detection and treatment
12/05/2002CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002CA2448101A1 Process for preparing a thialzole ppar-ligand and polymorphs thereof
12/05/2002CA2448081A1 Medicinal compositions
12/05/2002CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002CA2447657A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
12/05/2002CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002CA2445650A1 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
12/05/2002CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/05/2002CA2411549A1 Ligands of integrin receptors
12/04/2002EP1262490A1 GPib-LIPID BOND CONSTRUCT AND USE THEREOF
12/04/2002EP1262180A1 Tnf-alpha inhibitors
12/04/2002EP1261744A2 Estrogen receptor beta variants and methods of detection thereof
12/04/2002EP1261644A2 Modulation of the activity of the endothelial cell surface receptor ecrtp/dep-1 in the regulation of angiogenesis
12/04/2002EP1261640A2 Inflammation-related gene
12/04/2002EP1261639A2 Chondromodulin-i related peptide
12/04/2002EP1261636A2 Human protein kinases and protein kinase-like enzymes
12/04/2002EP1261635A1 Human polynucleotides, polypeptides, and antibodies
12/04/2002EP1261607A1 2,4-disubstituted thiazolyl derivatives
1 ... 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 ... 1272